Massive Lp(a) Cholesterol Study FAILED. Now What?

Summary

A large trial of pelacarsen, a drug that substantially lowers lipoprotein(a), or Lp(a), did not show an overall reduction in its combined cardiovascular outcome. The video argues that this result does not overturn the broader evidence that lowering atherogenic cholesterol particles can prevent heart disease. It may instead reflect limitations of the trial—or that Lp(a)-lowering could have benefits not captured by its main outcome.

Lp(a) is largely inherited, and the speaker says around one in five people have elevated levels. The video gives these approximate ranges:

• Below 75 nmol/L: normal
• 75–125 nmol/L: gray zone
• Above 125 nmol/L: high

Elevated Lp(a) is associated with cardiovascular disease and may also contribute to aortic stenosis, a narrowing of the heart’s aortic valve.

Why the trial may not have shown a benefit

The speaker offers five possible explanations, while emphasizing that none is established yet:

• Participants may already have had low apoB levels from other treatment, leaving less additional risk for Lp(a)-lowering to reduce.
• The trial’s target—a 20% reduction in cardiovascular events—may have been too ambitious for lowering Lp(a) over only a few years, given that Lp(a) exposure accumulates over a lifetime.
• The combined outcome included strokes, which the speaker says have not been as consistently linked to Lp(a) as some other cardiovascular events.
• Pelacarsen may not have lowered Lp(a) enough; newer experimental drugs have reportedly achieved larger reductions in early studies.
• The Lp(a) hypothesis could be wrong, but the speaker considers that premature given genetic evidence linking high Lp(a) with greater heart-attack risk.

Wellness and risk-reduction strategies discussed

• Consider measuring Lp(a) at least once in adulthood, especially because levels are mostly determined by genes.
• If Lp(a) is high, focus on overall cardiovascular risk: maintain a healthy weight, support insulin sensitivity, eat a healthy diet, stay physically active, and manage blood pressure.
• Discuss lowering apoB with a healthcare professional. The speaker describes apoB reduction as an established way to prevent cardiovascular events and says patients may start with a low-dose statin, adding ezetimibe if needed.
• The speaker says he aims for apoB below 50 in his own clinic, a more aggressive target than current guidelines, and is more likely to consider PCSK9 inhibitors for patients with high Lp(a). Treatment choices should be individualized with a clinician.
• PCSK9 inhibitors lower apoB and can also reduce Lp(a), but the video describes their possible benefit for aortic stenosis as preliminary and says more research is needed.
• The speaker briefly promotes a potassium-and-fiber drink, describing it as containing 8 g of fiber and 500 mg of potassium per serving.

The video’s bottom line: the failed trial does not mean the cholesterol hypothesis is wrong or that people with high Lp(a) should wait for a dedicated Lp(a) drug. The speaker recommends addressing proven cardiovascular risk factors, particularly apoB, with a clinician.

Presenter and sources

• Presenter: Dr. Brad Stanfield
• Research sources mentioned: Lp(a) HORIZON trial; Framingham Study; European consensus on Lp(a); genetic and observational research; PCSK9-inhibitor studies; and statin-based studies of aortic stenosis.